PDE4A and chronic obstructive pulmonary disease: Recently, a novel dual inhibitor of PDE3 and PDE4, Ensifentrine (C26H31N5O4) from Verona Pharma, was approved by the FDA as a maintenance treatment for patients with COPD [56,89].